Alliance for Multispecialty Research, LLC

Tempe, Arizona 85281

0 studies enrolling now · 13 studies all time

What they study most

COVID-19, Cardiovascular Diseases, Chikungunya Virus, Chikungunya Virus Infection, Chronic Kidney Disease, Chronic Low-back Pain, Diabetic Neuropathic Pain, Genital Herpes Simplex Type 2, Influenza, Lower Respiratory Tract Illness, Malaria, Obesity

Studies at this site

• A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain — Recruiting now
• Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination — Running, not enrolling
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals — Completed
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. — Completed
• Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers — Completed
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions — Running, not enrolling
• Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria — Completed
• A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) — Completed